Arnold Louie,
ASO PRG DIR & PROF
Department:
MD-INST FOR THERAPEUTIC INNOV
Business Phone:
(407) 313-7061
Business Email:
alouie@ufl.edu
Teaching Profile
Courses Taught
2021,2023-2024
PHA6133 Translational Clinical Pharmacology
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-6227-7580
Publications
2024
Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125–1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea
Journal of Antimicrobial Chemotherapy.
[DOI] 10.1093/jac/dkae063.
2024
Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models
Antimicrobial Agents and Chemotherapy.
68(3)
[DOI] 10.1128/aac.01394-23.
[PMID] 38289076.
2023
Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice
Antimicrobial Agents and Chemotherapy.
67(5)
[DOI] 10.1128/aac.00197-23.
[PMID] 37022153.
2023
Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against Neisseria gonorrhoeae in a gonococcal hollow-fiber infection model.
Frontiers in pharmacology.
14
[DOI] 10.3389/fphar.2023.1291885.
[PMID] 38130409.
2022
Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype
Antimicrobial Agents and Chemotherapy.
66(10)
[DOI] 10.1128/aac.00695-22.
[PMID] 36165631.
2022
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid
International Journal of Antimicrobial Agents.
59(2)
[DOI] 10.1016/j.ijantimicag.2021.106509.
2022
Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections.
Frontiers in pharmacology.
13
[DOI] 10.3389/fphar.2022.1035841.
[PMID] 36452226.
2021
Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase
Antimicrobial Agents and Chemotherapy.
65(10)
[DOI] 10.1128/aac.00693-21.
2021
Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.
Clinical pharmacology and therapeutics.
109(4):1000-1020
[DOI] 10.1002/cpt.2205.
[PMID] 33576025.
2021
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression.
Antimicrobial agents and chemotherapy.
65(4)
[DOI] 10.1128/AAC.02533-20.
[PMID] 33468465.
2021
Emergence of Resistance to Ceftazidime-Avibactam in a Pseudomonas aeruginosa Isolate Producing Derepressed blaPDC in a Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy.
65(6)
[DOI] 10.1128/AAC.00124-21.
[PMID] 33782013.
2021
Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model.
Frontiers in pharmacology.
12
[DOI] 10.3389/fphar.2021.682135.
[PMID] 34093206.
2021
Polymyxin B Pharmacodynamics in the Hollow-Fiber Infection Model: What You See May Not Be What You Get
Antimicrobial Agents and Chemotherapy.
65(8)
[DOI] 10.1128/aac.01853-20.
2021
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
Antimicrobial agents and chemotherapy.
65(2)
[DOI] 10.1128/AAC.02172-20.
[PMID] 33199386.
2020
Building Optimal Three-Drug Combination Chemotherapy Regimens.
Antimicrobial agents and chemotherapy.
64(11)
[DOI] 10.1128/AAC.01610-20.
[PMID] 32900682.
2020
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
Antimicrobial agents and chemotherapy.
64(12)
[DOI] 10.1128/AAC.01376-20.
[PMID] 32958720.
2020
First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus.
Antimicrobial agents and chemotherapy.
65(1)
[DOI] 10.1128/AAC.01956-20.
[PMID] 33106266.
2020
Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae.
mBio.
11(1)
[DOI] 10.1128/mBio.03189-19.
[PMID] 32047131.
2020
Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
151
[DOI] 10.1016/j.ejps.2020.105421.
[PMID] 32531349.
2019
Breakpoint determination when multiple organisms are tested for effect targets.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
130:196-199
[DOI] 10.1016/j.ejps.2019.01.033.
[PMID] 30711687.
2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.
Antimicrobial agents and chemotherapy.
63(7)
[DOI] 10.1128/AAC.00425-19.
[PMID] 30988147.
2019
Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.
International journal of antimicrobial agents.
53(3):275-283
[DOI] 10.1016/j.ijantimicag.2018.10.012.
[PMID] 30385322.
2019
Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay.
Antimicrobial agents and chemotherapy.
63(1)
[DOI] 10.1128/AAC.01695-18.
[PMID] 30397058.
2019
Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.
Clinical pharmacokinetics.
58(2):143-156
[DOI] 10.1007/s40262-018-0678-x.
[PMID] 29936678.
2019
GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens.
Antimicrobial agents and chemotherapy.
63(12)
[DOI] 10.1128/AAC.00834-19.
[PMID] 31548183.
2019
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.
Antimicrobial agents and chemotherapy.
63(5)
[DOI] 10.1128/AAC.02307-18.
[PMID] 30833428.
2019
Natural history of Acinetobacter baumannii infection in mice.
PloS one.
14(7)
[DOI] 10.1371/journal.pone.0219824.
[PMID] 31318907.
2019
Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of Klebsiella pneumoniae in a Hollow Fiber Infection Model.
Antimicrobial agents and chemotherapy.
63(8)
[DOI] 10.1128/AAC.00462-19.
[PMID] 31160285.
2018
Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy.
62(12)
[DOI] 10.1128/AAC.01470-18.
[PMID] 30249693.
2018
Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model.
Antimicrobial agents and chemotherapy.
62(6)
[DOI] 10.1128/AAC.02627-17.
[PMID] 29581114.
2018
Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.
Antimicrobial agents and chemotherapy.
62(1)
[DOI] 10.1128/AAC.01323-17.
[PMID] 29038277.
2018
Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay.
Antimicrobial agents and chemotherapy.
62(8)
[DOI] 10.1128/AAC.00856-18.
[PMID] 29866874.
2018
Erratum for Drusano et al., “Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia”.
Antimicrobial agents and chemotherapy.
62(4)
[DOI] 10.1128/AAC.00198-18.
[PMID] 29588353.
2018
First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae.
Antimicrobial agents and chemotherapy.
62(6)
[DOI] 10.1128/AAC.00282-18.
[PMID] 29712652.
2018
Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy.
62(8)
[DOI] 10.1128/AAC.00221-18.
[PMID] 29866864.
2018
The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy.
62(12)
[DOI] 10.1128/AAC.01682-18.
[PMID] 30249700.
2016
Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.
Antimicrobial agents and chemotherapy.
60(3):1834-40
[DOI] 10.1128/AAC.02887-15.
[PMID] 26824958.
2015
Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.
The Journal of infectious diseases.
211(8):1326-33
[DOI] 10.1093/infdis/jiu603.
[PMID] 25362196.
2015
Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States.
Antimicrobial agents and chemotherapy.
59(1):622-32
[DOI] 10.1128/AAC.03710-14.
[PMID] 25385113.
2015
Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
mBio.
6(6):e01741-15
[DOI] 10.1128/mBio.01741-15.
[PMID] 26530386.
2015
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.
Antimicrobial agents and chemotherapy.
60(3):1183-93
[DOI] 10.1128/AAC.02177-15.
[PMID] 26711759.
2015
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.
Antimicrobial agents and chemotherapy.
60(3):1194-201
[DOI] 10.1128/AAC.02231-15.
[PMID] 26711766.
2014
Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.
PloS one.
9(7)
[DOI] 10.1371/journal.pone.0101311.
[PMID] 25003557.
2014
Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Antimicrobial agents and chemotherapy.
58(6):3276-84
[DOI] 10.1128/AAC.02420-14.
[PMID] 24687492.
2014
Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.
The Journal of infectious diseases.
210(8):1319-24
[DOI] 10.1093/infdis/jiu237.
[PMID] 24760199.
2013
Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.
Antimicrobial agents and chemotherapy.
57(12):5946-60
[DOI] 10.1128/AAC.02616-12.
[PMID] 24041894.
2013
Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
Antimicrobial agents and chemotherapy.
57(6):2788-92
[DOI] 10.1128/AAC.02624-12.
[PMID] 23571540.
2013
Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice.
Antimicrobial agents and chemotherapy.
57(5):2010-5
[DOI] 10.1128/AAC.02504-12.
[PMID] 23403418.
2012
Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.
Antimicrobial agents and chemotherapy.
56(1):513-7
[DOI] 10.1128/AAC.05724-11.
[PMID] 22064542.
2012
Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
Antimicrobial agents and chemotherapy.
56(6):3054-7
[DOI] 10.1128/AAC.06383-11.
[PMID] 22470118.
2012
Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.
Antimicrobial agents and chemotherapy.
56(2):682-6
[DOI] 10.1128/AAC.05664-11.
[PMID] 22083484.
2012
Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
Antimicrobial agents and chemotherapy.
56(3):1229-39
[DOI] 10.1128/AAC.01109-10.
[PMID] 22155821.
2012
Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.
Antimicrobial agents and chemotherapy.
56(3):1170-81
[DOI] 10.1128/AAC.05383-11.
[PMID] 22155837.
2012
Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.
Antimicrobial agents and chemotherapy.
56(1):258-70
[DOI] 10.1128/AAC.05005-11.
[PMID] 22024819.
2012
Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy.
56(1):231-42
[DOI] 10.1128/AAC.05252-11.
[PMID] 22005996.
2011
Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy.
55(6):2623-8
[DOI] 10.1128/AAC.01374-10.
[PMID] 21486959.
2011
Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.
Antimicrobial agents and chemotherapy.
55(7):3295-304
[DOI] 10.1128/AAC.01324-10.
[PMID] 21502626.
2011
Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model.
Antimicrobial agents and chemotherapy.
55(11):5300-5
[DOI] 10.1128/AAC.00502-11.
[PMID] 21911576.
2011
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
Antimicrobial agents and chemotherapy.
55(7):3453-60
[DOI] 10.1128/AAC.01565-10.
[PMID] 21502615.
2011
Optimization of aminoglycoside therapy.
Antimicrobial agents and chemotherapy.
55(6):2528-31
[DOI] 10.1128/AAC.01314-10.
[PMID] 21402835.
2011
Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system.
PLoS computational biology.
7(2)
[DOI] 10.1371/journal.pcbi.1001073.
[PMID] 21304935.
2011
Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients.
Current pharmaceutical biotechnology.
12(12):2044-61
[PMID] 21554212.
2010
Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model.
Antimicrobial agents and chemotherapy.
54(10):4368-72
[DOI] 10.1128/AAC.00133-10.
[PMID] 20516275.
2010
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
Antimicrobial agents and chemotherapy.
54(6):2638-45
[DOI] 10.1128/AAC.01721-09.
[PMID] 20308371.
2010
The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
Antimicrobial agents and chemotherapy.
54(6):2646-54
[DOI] 10.1128/AAC.00065-10.
[PMID] 20368395.
2010
The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
mBio.
1(3)
[DOI] 10.1128/mBio.00139-10.
[PMID] 20802826.
2009
Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.
Antimicrobial agents and chemotherapy.
53(6):2266-73
[DOI] 10.1128/AAC.01680-08.
[PMID] 19289521.
2009
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
Antimicrobial agents and chemotherapy.
53(8):3325-30
[DOI] 10.1128/AAC.00006-09.
[PMID] 19364849.
2008
Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?
Antimicrobial agents and chemotherapy.
52(11):3973-9
[DOI] 10.1128/AAC.00453-08.
[PMID] 18725437.
2007
Back to the future: using aminoglycosides again and how to dose them optimally.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
45(6):753-60
[PMID] 17712761.
2007
Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
The Journal of infectious diseases.
196(5):782-7
[PMID] 17674322.
2007
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.
Antimicrobial agents and chemotherapy.
51(11):3781-8
[PMID] 17724157.
2007
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.
Antimicrobial agents and chemotherapy.
51(1):285-95
[PMID] 17088486.
2007
Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
Antimicrobial agents and chemotherapy.
51(8):2661-7
[PMID] 17517837.
2007
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy.
51(11):3988-4000
[PMID] 17846144.
2007
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
Antimicrobial agents and chemotherapy.
51(7):2329-36
[PMID] 17438043.
2007
Isoniazid’s bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
The Journal of infectious diseases.
195(2):194-201
[PMID] 17191164.
2007
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Antimicrobial agents and chemotherapy.
51(3):968-74
[PMID] 17194830.
2007
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
Antimicrobial agents and chemotherapy.
51(10):3760-2
[PMID] 17682101.
2007
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
44(1):79-86
[PMID] 17143821.
2007
The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance.
Antimicrobial agents and chemotherapy.
51(2):744-7
[PMID] 17116679.
2007
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
44(1):2-12
[PMID] 17143808.
2006
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Antimicrobial agents and chemotherapy.
50(11):3695-700
[PMID] 16954319.
2006
Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.
Antimicrobial agents and chemotherapy.
50(11):3680-8
[PMID] 16954320.
2006
Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy.
50(1):310-7
[PMID] 16377702.
2006
The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
42(4):525-32
[PMID] 16421797.
2005
Bacterial-population responses to drug-selective pressure: examination of garenoxacin’s effect on Pseudomonas aeruginosa.
The Journal of infectious diseases.
192(3):420-8
[PMID] 15995955.
2005
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Antimicrobial agents and chemotherapy.
49(12):5099-106
[PMID] 16304178.
2005
Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
Antimicrobial agents and chemotherapy.
49(8):3178-81
[PMID] 16048921.
2005
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
Antimicrobial agents and chemotherapy.
49(12):5058-68
[PMID] 16304173.
2005
Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.
The Journal of infectious diseases.
192(4):673-80
[PMID] 16028137.
2004
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
The Journal of infectious diseases.
190(9):1642-51
[PMID] 15478070.
2003
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.
The Journal of clinical investigation.
112(2):275-85
[PMID] 12865415.
2003
Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.
Pharmacotherapy.
23(3):291-5
[PMID] 12627925.
Grants
Jan 2023
ACTIVE
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Oct 2022
ACTIVE
Identifying the optimal combination of macrolide-containing and macrolide-sparing oral antibiotic regimens to administer with SPR719/SPR720 to maximize the killing of macrolide susceptible and resistant strains of Mycobacterium avium Complex (MAC)
Role: Principal Investigator
Funding: SPERO THERAPEUTICS
Sep 2022
ACTIVE
Battelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)
Role: Co-Investigator
Funding: BATTELLE MEMORIAL INST
via DEFENSE THREAT REDUCTION AGENCY
Jul 2022
ACTIVE
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant staphylococci.
Role: Principal Investigator
Funding: PROKARYOTICS
via NATL INST OF HLTH NIAID
Oct 2021
– Aug 2023
Efficacy of the polypeptide antibiotic SPR206 when administered alone and in combination with beta-lactam partner antibiotics for the killing of multidrug-resistant nosocomial Gram-negative bacterial pathogens and the impact of combination therapy on resi
Role: Principal Investigator
Funding: SPERO THERAPEUTICS
Aug 2021
– Aug 2022
Pharmacokinetic-Pharmacodynamic Studies to Support Dose Selection for Tebipenem for the Treatment of Mycobacterium avium Complex Pulmonary Disease
Role: Principal Investigator
Funding: SPERO THERAPEUTICS
Mar 2021
ACTIVE
Development of CZ-02s (AIIPS), a New Class of Antibacterial for the Treatment of Drug-Resistant Bacterial Infections, including those caused by Multidrug-Resistant Yersinia pestis, Francisella tularensis, and Burkholderia mallei
Role: Co-Investigator
Funding: ADVANCED TECHNOLOGY INTERNATIONAL
via DEFENSE THREAT REDUCTION AGENCY
Nov 2020
– Dec 2021
Project Bioshield
Role: Co-Investigator
Funding: SPERO THERAPEUTICS
Jun 2020
– May 2023
A Mechanism Based Approach to Metallo beta-Lactamase Inhibition
Role: Co-Investigator
Funding: CASE WESTERN RESERVE UNIV
via NATL INST OF HLTH NIAID
Apr 2020
ACTIVE
Battelle Subcontract 778380 SAB Year 1
Role: Co-Investigator
Funding: BATTELLE MEMORIAL INST
via DEFENSE THREAT REDUCTION AGENCY
Dec 2019
ACTIVE
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs
Role: Co-Investigator
Funding: STATE UNIV OF NEW YORK BUFFALO
via NATL INST OF HLTH NIAID
Nov 2019
– Oct 2021
Ceftazidime/Avibactam plus Aminoglycoside for Ceftazidime/Avibactam Resistant KPC-3 Klebsiella pneumonia
Role: Principal Investigator
Funding: ALLERGAN SALES
Aug 2018
ACTIVE
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jun 2018
– May 2021
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome
Role: Principal Investigator
Funding: CURZA
via NATL INST OF HLTH NIAID
Jan 2018
– Jun 2019
CZ-02 pharmacodynamic studies, A New Class of Antibiotics Selectively Inhibiting Bacterial Protein Synthesis
Role: Principal Investigator
Funding: CURZA
via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Nov 2017
– Oct 2023
Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Sep 2017
– Dec 2021
A Preclinical Mouse Model of Acinetobacter buamannii Infection For Antibacterial Development
Role: Co-Investigator
Funding: UNIV OF SOUTHERN CALIFORNIA
via US FOOD AND DRUG ADMN
Jun 2017
– Jun 2019
Can ceftazidime-avibactam be pharmacodynamically-optimized to prevent emergence of resistance by KPC3-expressing Enterobacteriaceae?
Role: Principal Investigator
Funding: ALLERGAN SALES
Jun 2017
– May 2021
OR-DRPD-ROF2017:Combating resistant Gram-negative bacterial superbugs via omics techniques
Role: Co-Investigator
Funding: UF DSR OPPORTUNITY FUND
Aug 2016
– Jul 2022
Optimizing combination therapy for accelerate clinical cure of tuberculosis
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Aug 2016
– Sep 2017
Dose-fractionation study for AKPN001 (ATCC 43816) for plazomicin and the pharmacokinetics-pharmacodynamics of amikacin
Role: Principal Investigator
Funding: ACHAOGEN
via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Jul 2016
– May 2018
Pharmacokinetics-Pharmacodynamics of RG-6080, a Potent Non-Beta-Lactam Beta-Lactamase Inhibitor, In Combination with Meropenem, Piperacillin, and/or Cefepime for the Killing of Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa in Neutropen
Role: Principal Investigator
Funding: F HOFFMANN LA ROCHE
Jun 2016
– Oct 2017
aIn vitro Hollow Fiber Pharmacodynamic Studies to Identify the Dose nd Frequency of Administration of Iclaprim that Optimizes the Killing of MRSA and Prevents the Emergence of Drug-Resistance During Therapy
Role: Principal Investigator
Funding: MOTIF BIOSCIENCES INC
Jun 2016
– May 2019
Nitroxoline Small Molecules as Cures for Persistent Bacterial Infections
Role: Project Manager
Funding: UF DSR OPPORTUNITY FUND
Jan 2016
– Jun 2017
DOSE-RANGE STUDIES FOR PLAZOMICIN IN NEUTROPENIC MURINEPNEUMONIA & THIGH INFECTION MODELS AGAINST CARBAPENEM……
Role: Principal Investigator
Funding: ACHAOGEN
via US DEPT OF HLTH AND HUMAN SER
Dec 2015
– May 2021
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Aug 2014
– Apr 2017
Combination Therapy Modeling for M tuberculosis Resistance Suppression and Kill
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Aug 2014
– Jun 2016
Efficacy of oxazolidinones alone in in vitro EBA studies & in polydrug TB therapy
Role: Principal Investigator
Funding: MIRIAM HOSPITAL
via NATL INST OF HLTH NIAID
Contact Details
Phones:
- Business:
- (407) 313-7061
Emails:
- Business:
- alouie@ufl.edu
Addresses:
- Business Mailing:
-
6550 SANGER RD
ORLANDO FL 32827 - Business Street:
-
6550 SANGER RD
ORLANDO FL 32827